JP2015509540A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509540A5
JP2015509540A5 JP2014561069A JP2014561069A JP2015509540A5 JP 2015509540 A5 JP2015509540 A5 JP 2015509540A5 JP 2014561069 A JP2014561069 A JP 2014561069A JP 2014561069 A JP2014561069 A JP 2014561069A JP 2015509540 A5 JP2015509540 A5 JP 2015509540A5
Authority
JP
Japan
Prior art keywords
alk
disorder
compound
salt
fak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014561069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509540A (ja
JP6016953B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/029304 external-priority patent/WO2013134353A1/en
Publication of JP2015509540A publication Critical patent/JP2015509540A/ja
Publication of JP2015509540A5 publication Critical patent/JP2015509540A5/ja
Application granted granted Critical
Publication of JP6016953B2 publication Critical patent/JP6016953B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014561069A 2012-03-06 2013-03-06 二重のalkおよびfak阻害剤としての縮合二環式2,4−ジアミノピリミジン誘導体 Expired - Fee Related JP6016953B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607305P 2012-03-06 2012-03-06
US61/607,305 2012-03-06
PCT/US2013/029304 WO2013134353A1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016188585A Division JP2017039741A (ja) 2012-03-06 2016-09-27 二重のalkおよびfak阻害剤としての縮合二環式2,4−ジアミノピリミジン誘導体

Publications (3)

Publication Number Publication Date
JP2015509540A JP2015509540A (ja) 2015-03-30
JP2015509540A5 true JP2015509540A5 (enExample) 2016-02-25
JP6016953B2 JP6016953B2 (ja) 2016-10-26

Family

ID=47892060

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014561069A Expired - Fee Related JP6016953B2 (ja) 2012-03-06 2013-03-06 二重のalkおよびfak阻害剤としての縮合二環式2,4−ジアミノピリミジン誘導体
JP2016188585A Pending JP2017039741A (ja) 2012-03-06 2016-09-27 二重のalkおよびfak阻害剤としての縮合二環式2,4−ジアミノピリミジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016188585A Pending JP2017039741A (ja) 2012-03-06 2016-09-27 二重のalkおよびfak阻害剤としての縮合二環式2,4−ジアミノピリミジン誘導体

Country Status (28)

Country Link
US (5) US9132128B2 (enExample)
EP (2) EP3056494B1 (enExample)
JP (2) JP6016953B2 (enExample)
KR (1) KR102068374B1 (enExample)
CN (2) CN104159894B (enExample)
AU (1) AU2013229995B2 (enExample)
CA (1) CA2865420C (enExample)
CL (1) CL2014002353A1 (enExample)
CY (1) CY1117565T1 (enExample)
DK (1) DK2822939T3 (enExample)
EA (2) EA025859B1 (enExample)
ES (2) ES2570976T3 (enExample)
HR (1) HRP20160387T1 (enExample)
HU (1) HUE027976T2 (enExample)
IL (2) IL234239A (enExample)
ME (1) ME02460B (enExample)
MX (2) MX347772B (enExample)
MY (1) MY177290A (enExample)
NZ (1) NZ630251A (enExample)
PH (1) PH12014501979A1 (enExample)
PL (1) PL2822939T3 (enExample)
RS (1) RS54689B1 (enExample)
SG (2) SG10201507865QA (enExample)
SI (1) SI2822939T1 (enExample)
SM (1) SMT201600134B (enExample)
UA (1) UA115052C2 (enExample)
WO (1) WO2013134353A1 (enExample)
ZA (1) ZA201406147B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115052C2 (uk) * 2012-03-06 2017-09-11 Сефалон, Інк. Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016105529A1 (en) 2014-12-23 2016-06-30 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
MX2021001398A (es) 2018-08-07 2021-08-16 In3Bio Ltd Métodos y composiciones para la inhibición de la vía egf/egfr en combinación con inhibidores de la cinasa del linfoma anaplásico.
WO2024178339A2 (en) * 2023-02-23 2024-08-29 The Regents Of The University Of Michigan Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP4607879B2 (ja) 2003-08-15 2011-01-05 ノバルティス アーゲー 新生物疾患、炎症および免疫障害の処置に有用な2,4−ピリミジンジアミン
PL1713806T3 (pl) * 2004-02-14 2013-09-30 Irm Llc Związki i kompozycje jako inhibitory kinaz białkowych
AU2005230847B2 (en) 2004-03-31 2012-11-08 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US8962643B2 (en) * 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
JP5512274B2 (ja) * 2006-10-23 2014-06-04 セファロン、インク. ALK阻害剤およびc−MET阻害剤としての2,4−ジアミノピリミジンの縮合二環式誘導体
RS53588B1 (sr) * 2006-12-08 2015-02-27 Irm Llc Jedinjenja i kompozicije kao inhibitori protein kinaza
JP4782239B2 (ja) * 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
HUE046402T2 (hu) * 2009-06-10 2020-03-30 Chugai Pharmaceutical Co Ltd Tetraciklusos vegyületek
UA115052C2 (uk) * 2012-03-06 2017-09-11 Сефалон, Інк. Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор
KR101446742B1 (ko) * 2012-08-10 2014-10-01 한국화학연구원 N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2016105529A1 (en) * 2014-12-23 2016-06-30 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives

Similar Documents

Publication Publication Date Title
JP2015509540A5 (enExample)
JP2015536964A5 (enExample)
EA201690322A1 (ru) Терапевтически активные соединения и способы их применения
JP2016501221A5 (enExample)
JP2013064024A5 (enExample)
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP2016533366A5 (enExample)
NZ628078A (en) Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
JP2016516808A5 (enExample)
JP2015512398A5 (enExample)
JP2017537066A5 (enExample)
JP2013522326A5 (enExample)
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
JP2014527042A5 (enExample)
MY158494A (en) Pharmaceutically active compounds as axl inhibitors
CA2922684A1 (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
EA201690741A1 (ru) Составы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
HRP20160387T1 (hr) Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
HRP20230477T1 (hr) Spojevi i pripravci uree kao inhibitori smarca2/brm-atpaze
JP2015502926A5 (enExample)
JP2014509653A5 (enExample)
JP2017514806A5 (enExample)
MX2016002795A (es) Compuestos de triazolona y usos de los mismos.